Collaborators

our people

MR&D_Header_900x390_Collaborators

Collaboration expands our clinical and therapeutic expertise as well as our ability to address unmet medical needs. Our academic partners are internationally recognized experts in target indications, outcomes research and disease assessment. Their contributions are fundamental to the design and conduct of efficient trials and improved patient outcomes.

Dot

Collaborators

Eileen Crowley

MD, MSc - Pediatric Gastroenterologist, Scientific Collaborator

Eileen Crowley

MD, MSc - Pediatric Gastroenterologist, Scientific Collaborator
Dr. Eileen Crowley completed her honours medical degree at the National University of Ireland and subspecialty training with the Royal College of Physicians, Ireland. Moving to SickKids, Toronto for fellowship training in Pediatric Gastroenterology, Hepatology and Nutrition and submitted her Master’s thesis entitled ‘Towards Personalized Care in Pediatric Inflammatory Bowel Disease’. She completed postdoctoral training and subspecialty Pediatric Inflammatory Bowel Disease training in the laboratory of Dr Aleixo Muise and received CIHR grant funding for supports.  She was co-supervised by Dr Anne Griffiths working on the Canadian (CIDsCaNN) IBD network.
Dr Crowley’s area of clinical specialty include pediatric IBD.  Her research interests include pediatric IBD, the genetics of IBD, therapeutic drug monitoring and precision medicine.  Her work has served to better delineate the genetic phenotype of children with IBD as well as optimizing response to therapy in this age group.
Dr Crowley works as a Pediatric Gastroenterologist at the Children’s Hospital, London Health Sciences, Ontario, as an Assistant Professor with Western University and Clinician Investigator in Pediatric IBD.  Dr Crowley intends to pursue further research in index development and clinical trials in Pediatric IBD.

Rohit Loomba

MD, MHSc – Scientific Collaborator

Rohit Loomba

MD, MHSc – Scientific Collaborator

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of NAFLD using advanced imaging modalities. 

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 25 clinical trials conducted worldwide. He holds two patents on non-invasive biomarkers of NAFLD and fibrosis.

His research is funded by the National Institutes of Health as a Principal Investigator currently leading three R01, a P01 and a U01 grant.

He is the Deputy Editor of hepatology, the official journal of the AASLD.

Dr. Loomba has published more than 250 manuscripts and has an H-index of 73. He is among the top 1% of the globally highly cited scientists across all fields in 2019 by Web of Science. He is an elected member of American Society of Clinical Investigation.


Evan S. Dellon

MD, MPH - Scientific Collaborator

Evan S. Dellon

MD, MPH - Scientific Collaborator

Evan S. Dellon, MD, MPH, is a Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina School of Medicine in Chapel Hill.

Dr. Dellon received his undergraduate degree from Brown University and his medical degree from Johns Hopkins School of Medicine. He completed internship and residency in Internal Medicine at Massachusetts General Hospital. He performed a clinical and a research fellowship in Adult Gastroenterology at UNC, during which he also received a Masters of Public Health degree in Epidemiology from the UNC School of Public Health.

Dr. Dellon joined the UNC faculty and the Center for Esophageal Diseases and Swallowing (CEDAS) in 2008, where his main clinical focus is on disorders of swallowing, and in particular eosinophilic esophagitis (EoE) and other eosinophilic GI diseases (EGIDs). He became Director of CEDAS in 2014.

Dr. Dellon’s research interests span the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of EoE and EGIDs. The goal of his research is to improve the lives of patients with EoE/EGIDs by learning how to better diagnose, treat, and monitor the conditions. He is widely published in this area, and has more than 265 peer-reviewed papers in the medical literature overall.

Dr. Dellon is also an Associate Editor for Clinical Gastroenterology and Hepatology. He collaborates with and advises Alimentiv Clinical Trials on studies related to EoE and EGIDs, including the areas of trial design, patient outcomes, and endpoint development.



Eileen Crowley

MD, MSc - Pediatric Gastroenterologist, Scientific Collaborator
Dr. Eileen Crowley completed her honours medical degree at the National University of Ireland and subspecialty training with the Royal College of Physicians, Ireland. Moving to SickKids, Toronto for fellowship training in Pediatric Gastroenterology, Hepatology and Nutrition and submitted her Master’s thesis entitled ‘Towards Personalized Care in Pediatric Inflammatory Bowel Disease’. She completed postdoctoral training and subspecialty Pediatric Inflammatory Bowel Disease training in the laboratory of Dr Aleixo Muise and received CIHR grant funding for supports.  She was co-supervised by Dr Anne Griffiths working on the Canadian (CIDsCaNN) IBD network.
Dr Crowley’s area of clinical specialty include pediatric IBD.  Her research interests include pediatric IBD, the genetics of IBD, therapeutic drug monitoring and precision medicine.  Her work has served to better delineate the genetic phenotype of children with IBD as well as optimizing response to therapy in this age group.
Dr Crowley works as a Pediatric Gastroenterologist at the Children’s Hospital, London Health Sciences, Ontario, as an Assistant Professor with Western University and Clinician Investigator in Pediatric IBD.  Dr Crowley intends to pursue further research in index development and clinical trials in Pediatric IBD.


Rohit Loomba

MD, MHSc – Scientific Collaborator

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of NAFLD using advanced imaging modalities. 

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 25 clinical trials conducted worldwide. He holds two patents on non-invasive biomarkers of NAFLD and fibrosis.

His research is funded by the National Institutes of Health as a Principal Investigator currently leading three R01, a P01 and a U01 grant.

He is the Deputy Editor of hepatology, the official journal of the AASLD.

Dr. Loomba has published more than 250 manuscripts and has an H-index of 73. He is among the top 1% of the globally highly cited scientists across all fields in 2019 by Web of Science. He is an elected member of American Society of Clinical Investigation.



Evan S. Dellon

MD, MPH - Scientific Collaborator

Evan S. Dellon, MD, MPH, is a Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina School of Medicine in Chapel Hill.

Dr. Dellon received his undergraduate degree from Brown University and his medical degree from Johns Hopkins School of Medicine. He completed internship and residency in Internal Medicine at Massachusetts General Hospital. He performed a clinical and a research fellowship in Adult Gastroenterology at UNC, during which he also received a Masters of Public Health degree in Epidemiology from the UNC School of Public Health.

Dr. Dellon joined the UNC faculty and the Center for Esophageal Diseases and Swallowing (CEDAS) in 2008, where his main clinical focus is on disorders of swallowing, and in particular eosinophilic esophagitis (EoE) and other eosinophilic GI diseases (EGIDs). He became Director of CEDAS in 2014.

Dr. Dellon’s research interests span the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of EoE and EGIDs. The goal of his research is to improve the lives of patients with EoE/EGIDs by learning how to better diagnose, treat, and monitor the conditions. He is widely published in this area, and has more than 265 peer-reviewed papers in the medical literature overall.

Dr. Dellon is also an Associate Editor for Clinical Gastroenterology and Hepatology. He collaborates with and advises Alimentiv Clinical Trials on studies related to EoE and EGIDs, including the areas of trial design, patient outcomes, and endpoint development.


Arjan Bredenoord

MD, PhD - Scientific Collaborator

Arjan Bredenoord

MD, PhD - Scientific Collaborator

Albert J (Arjan) Bredenoord studied Medicine in Antwerp, Belgium. He subsequently worked on several clinical research projects on GI motility at the University of Utrecht, the Netherlands which resulted in a PhD thesis on gastroesophageal reflux disease in 2006. His clinical training was performed in Nieuwegein, the Netherlands and at the Royal London Hospital in London, UK. He currently works as a consultant Gastroenterologist at the Amsterdam University Medical Center where he is dedicated to patients care, scientific research and education in the field of benign esophageal diseases. He was appointed professor of Neurogastroenterology & Motility at the University of Amsterdam in 2019.

His main focus is on achalasia, reflux disease and eosinophilic esophagitis. The esophageal clinic in the AMC Amsterdam hosts the largest population of benign esophageal diseases in the Netherlands. Dr Bredenoord is an author of over 250 papers, books and book chapters on esophageal diseases and organizes regular courses in Europe, North America and Asia. Dr Bredenoord is President of the European Society of Eosinophilic Esophagitis EUREOS, member of the UEG Scientific Committee and co-founder of the International HRM working group. He collaborates with Alimentiv Clinical Trials on studies on endpoint development for clinical trials in eosinophilic esophagitis and advises on all stages of trial design in drug development for eosinophilic esophagitis.


Jordi Rimola

MD, PhD - Scientific Collaborator

Jordi Rimola

MD, PhD - Scientific Collaborator

Dr J Rimola MD PhD is a Radiologist subspecialized in abdominal and gastrointestinal imaging, and member of the Inflammatory Bowel Disease unit directed by Dr. Julian Panés in Barcelona. He has had a leading role in the application of cross-sectional imaging techniques to the study of Crohn’s disease, development and validation of activity indices, and implementation of MRE and pelvic MRI in multicentric clinical studies. He participated in the ECCO-ESGAR guidelines elaboration and in different other expert consensus and recommendations document.


Rish Pai

MD, PhD - Scientific Collaborator

Rish Pai

MD, PhD - Scientific Collaborator

Dr. Rish Pai received his BA from Pomona College in Claremont, CA and earned his MD, PhD from Case Western University School of Medicine in Cleveland, OH. He completed his anatomic pathology residency at the University of Chicago Medical Center, followed by a gastrointestinal and hepatic pathology fellowship at the same institution. Dr. Pai is currently Professor of Laboratory Medicine & Pathology and serves as a Consultant Pathologist at the Mayo Clinic in Phoenix, Arizona. Dr. Pai has lectured nationally and internationally on many aspects of gastrointestinal and hepatic pathology and has directed multiple GI CME courses. Dr. Pai is a regular reviewer for numerous pathology and gastroenterology journals and serves on the Editorial Board of the American Journal of Surgical Pathology. He has published over 110 articles and written multiple book chapters in the fields of gastrointestinal and hepatic pathology.  He is currently President of the Rodger C. Haggitt Gastrointestinal Pathology Society, member of the United States and Canadian Academy of Pathology (USCAP) Nominating Committee, and a former member of the USCAP Education Committee.

Dr. Pai works extensively with Alimentiv executive and scientific leaders in developing and validating histologic indices for clinical trials in inflammatory bowel disease, eosinophilic esophagitis, non-alcoholic steatohepatitis, and other diseases of the gastrointestinal tract. Dr. Pai also participates in protocol development, development of histologic endpoints, and precision medicine initiatives.



Arjan Bredenoord

MD, PhD - Scientific Collaborator

Albert J (Arjan) Bredenoord studied Medicine in Antwerp, Belgium. He subsequently worked on several clinical research projects on GI motility at the University of Utrecht, the Netherlands which resulted in a PhD thesis on gastroesophageal reflux disease in 2006. His clinical training was performed in Nieuwegein, the Netherlands and at the Royal London Hospital in London, UK. He currently works as a consultant Gastroenterologist at the Amsterdam University Medical Center where he is dedicated to patients care, scientific research and education in the field of benign esophageal diseases. He was appointed professor of Neurogastroenterology & Motility at the University of Amsterdam in 2019.

His main focus is on achalasia, reflux disease and eosinophilic esophagitis. The esophageal clinic in the AMC Amsterdam hosts the largest population of benign esophageal diseases in the Netherlands. Dr Bredenoord is an author of over 250 papers, books and book chapters on esophageal diseases and organizes regular courses in Europe, North America and Asia. Dr Bredenoord is President of the European Society of Eosinophilic Esophagitis EUREOS, member of the UEG Scientific Committee and co-founder of the International HRM working group. He collaborates with Alimentiv Clinical Trials on studies on endpoint development for clinical trials in eosinophilic esophagitis and advises on all stages of trial design in drug development for eosinophilic esophagitis.



Jordi Rimola

MD, PhD - Scientific Collaborator

Dr J Rimola MD PhD is a Radiologist subspecialized in abdominal and gastrointestinal imaging, and member of the Inflammatory Bowel Disease unit directed by Dr. Julian Panés in Barcelona. He has had a leading role in the application of cross-sectional imaging techniques to the study of Crohn’s disease, development and validation of activity indices, and implementation of MRE and pelvic MRI in multicentric clinical studies. He participated in the ECCO-ESGAR guidelines elaboration and in different other expert consensus and recommendations document.



Rish Pai

MD, PhD - Scientific Collaborator

Dr. Rish Pai received his BA from Pomona College in Claremont, CA and earned his MD, PhD from Case Western University School of Medicine in Cleveland, OH. He completed his anatomic pathology residency at the University of Chicago Medical Center, followed by a gastrointestinal and hepatic pathology fellowship at the same institution. Dr. Pai is currently Professor of Laboratory Medicine & Pathology and serves as a Consultant Pathologist at the Mayo Clinic in Phoenix, Arizona. Dr. Pai has lectured nationally and internationally on many aspects of gastrointestinal and hepatic pathology and has directed multiple GI CME courses. Dr. Pai is a regular reviewer for numerous pathology and gastroenterology journals and serves on the Editorial Board of the American Journal of Surgical Pathology. He has published over 110 articles and written multiple book chapters in the fields of gastrointestinal and hepatic pathology.  He is currently President of the Rodger C. Haggitt Gastrointestinal Pathology Society, member of the United States and Canadian Academy of Pathology (USCAP) Nominating Committee, and a former member of the USCAP Education Committee.

Dr. Pai works extensively with Alimentiv executive and scientific leaders in developing and validating histologic indices for clinical trials in inflammatory bowel disease, eosinophilic esophagitis, non-alcoholic steatohepatitis, and other diseases of the gastrointestinal tract. Dr. Pai also participates in protocol development, development of histologic endpoints, and precision medicine initiatives.